Pasithea Therapeutics Corp.
Clinical trials sponsored by Pasithea Therapeutics Corp., explained in plain language.
-
New pill targets tough cancers: early trial seeks safer doses
Disease control Recruiting nowThis early-phase study tests an experimental drug called PAS-004 in about 48 adults with advanced solid tumors that have certain gene mutations (RAS, NF1, or RAF). The main goal is to find a safe dose and understand side effects. Participants take the drug by mouth daily for up t…
Phase: PHASE1 • Sponsor: Pasithea Therapeutics Corp. • Aim: Disease control
Last updated May 26, 2026 05:51 UTC
-
New pill could shrink nerve tumors in NF1 patients
Disease control Recruiting nowThis early-stage trial tests an experimental drug called PAS-004 in adults with neurofibromatosis type 1 (NF1) who have at least one symptomatic, inoperable nerve tumor (plexiform neurofibroma). The study aims to find safe doses and check for side effects. Participants take a dai…
Phase: PHASE1 • Sponsor: Pasithea Therapeutics Corp. • Aim: Disease control
Last updated May 26, 2026 05:50 UTC